Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.78
(-2.26%)
EUR 0.78
(-2.26%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.38 Million | -970.46 Thousand | -394.77 Thousand | -501 Thousand | -405 Thousand | - |
| Net Income | -4.79 Million | -1.3 Million | -603.59 Thousand | 275 Thousand | -1.04 Million | -1.93 Million |
| Depreciation & Amortization | 330.11 Thousand | 319.63 Thousand | 247.72 Thousand | 51 Thousand | 55 Thousand | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 747.32 Thousand | 172.13 Thousand | 92.04 Thousand | -727 Thousand | 675 Thousand | - |
| Other non-cash items | 4.79 Million | 414.87 Thousand | 311.36 Thousand | -100 Thousand | -92 Thousand | 1.93 Million |
| Investing Cash Flow | -98.46 Thousand | -227.91 Thousand | -958.01 Thousand | -212 Thousand | -160 Thousand | - |
| Investments in PPE | -98.56 Thousand | -227.91 Thousand | -955.71 Thousand | -108 Thousand | -63 Thousand | - |
| Acquisitions | 100.00 | - | - | 372.00 | - | - |
| Investment purchases | - | - | -2300.00 | -1000.00 | -97 Thousand | - |
| Sales/Maturities of investments | - | - | - | -372.00 | - | - |
| Other Investing Activities | - | -149.6 Thousand | -958.01 Thousand | -103 Thousand | -158.54 Thousand | - |
| Financing Cash Flow | 42.00 | 2461.00 | 6.29 Million | -21 Thousand | 1000.00 | - |
| Debt repayment | - | - | -2725.00 | -2231.00 | -999.00 | - |
| Dividends payments | - | - | - | -20.71 Thousand | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 42.00 | 2461.00 | 6.29 Million | - | - | - |
| Other Financing Activities | - | 2461.00 | 6.29 Million | 2231.00 | - | - |
| Accounts receivables | -61.79 Thousand | 108.47 Thousand | 143.52 Thousand | -369.5 Thousand | -4411.00 | - |
| Accounts payables | 674.63 Thousand | 2296.00 | -70.18 Thousand | 141.69 Thousand | - | - |
| Inventory | -73.3 Thousand | -40.85 Thousand | -20.21 Thousand | 12 Thousand | 32 Thousand | - |
| Other working capital | 207.79 Thousand | 102.22 Thousand | 38.92 Thousand | -511.19 Thousand | 643 Thousand | - |
| Cash at beginning of period | 3.79 Million | 4.98 Million | 43.01 Thousand | 776 Thousand | 1.34 Million | - |
| Cash at end of period | 2.3 Million | 3.79 Million | 4.98 Million | 43 Thousand | 776 Thousand | - |
| Capital Expenditure | -98.56 Thousand | -227.91 Thousand | -955.71 Thousand | -108 Thousand | -63 Thousand | - |
| Effect of forex changes on cash | - | - | - | 1000.00 | -1000.00 | - |
| Net cash flow / Change in cash | -1.48 Million | -1.19 Million | 4.94 Million | -733 Thousand | -565 Thousand | - |
| Free Cash Flow | -1.48 Million | -1.19 Million | -1.35 Million | -609 Thousand | -468 Thousand | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.53 Million | -1.53 Million | -2.47 Million | -1.94 Million | -1.94 Million | -899.56 Thousand |
| Depreciation & Amortization | 703.39 Thousand | 703.39 Thousand | 330.11 Thousand | 171.29 Thousand | - | 158.82 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 178.96 Thousand | 178.96 Thousand | 747.32 Thousand | 819.91 Thousand | - | -72.58 Thousand |
| Other non-cash items | -319.21 Thousand | -319.21 Thousand | 130.46 Thousand | 1.94 Million | 1.94 Million | 573.55 Thousand |
| Investing Cash Flow | -10 Thousand | -10 Thousand | -98.46 Thousand | -7937.00 | - | -90.52 Thousand |
| Investments in PPE | -2509.00 | -2509.00 | -98.56 Thousand | -7937.00 | - | -90.62 Thousand |
| Acquisitions | - | - | 100.00 | - | - | 100.00 |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -7492.00 | -7492.00 | - | - | - | -30.29 Thousand |
| Financing Cash Flow | 200.23 Thousand | 200.23 Thousand | 42.00 | -1653.00 | - | 1695.00 |
| Debt repayment | -55.36 Thousand | - | - | -1695.00 | - | -1695.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 455.84 Thousand | - | 42.00 | 42.00 | - | - |
| Other Financing Activities | 200.23 Thousand | 200.23 Thousand | - | - | - | 848.00 |
| Accounts receivables | 98.49 Thousand | 98.49 Thousand | -61.79 Thousand | 83.88 Thousand | - | -145.68 Thousand |
| Accounts payables | -713.16 Thousand | - | 674.63 Thousand | 702.99 Thousand | - | -28.36 Thousand |
| Inventory | -10.37 Thousand | -10.37 Thousand | -73.3 Thousand | -5210.00 | - | -68.09 Thousand |
| Other working capital | 90.84 Thousand | 90.84 Thousand | 207.79 Thousand | 38.25 Thousand | - | 169.54 Thousand |
| Cash at beginning of period | 2.3 Million | - | 3.79 Million | 2.9 Million | - | 3.79 Million |
| Cash at end of period | -781.24 Thousand | -781.24 Thousand | 2.3 Million | 2.3 Million | - | 2.9 Million |
| Capital Expenditure | -2509.00 | -2509.00 | -98.56 Thousand | -7937.00 | - | -90.62 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -3.09 Million | -781.24 Thousand | -1.48 Million | -595.44 Thousand | - | -888.38 Thousand |
| Free Cash Flow | -973.98 Thousand | -973.98 Thousand | -1.48 Million | -593.79 Thousand | - | -890.18 Thousand |
SIRCA
SOLS
8886
7231
300407
CCLD